Kerala Doctor Loses 31 kg on Retatrutide Trial as 12 mg Dose Cut Weight 28.3%
Updated
Updated · The Indian Express · Jul 13
Kerala Doctor Loses 31 kg on Retatrutide Trial as 12 mg Dose Cut Weight 28.3%
1 articles · Updated · The Indian Express · Jul 13
Summary
Dr. Nabin dropped from 120 kg to 89 kg over two years on experimental obesity drug Retatrutide after diet and exercise alone had reduced only 10 kg.
Retatrutide targets three receptors—GLP-1, GIP and glucagon—and a Phase 3 trial showed average weight loss of 19% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg over 80 weeks.
Weekly diarrhoea disrupted his work and forced leave once or twice a month, while Dysesthesia—reported in 5.1% to 12.5% of trial participants—caused tingling and skin sensitivity.
Rapid weight loss also brought muscle loss, body-image strain and social stigma; a 167-person study presented by his trial centre linked GLP-1 dropouts partly to negative comments about looking too thin or ill.
Doctors say such drugs could replace up to 95% of bariatric surgeries, but Nabin has already started regaining weight after the trial, underscoring the need for long-term treatment plus diet, exercise and sleep.
If weight is regained after stopping, are next-gen obesity drugs a lifelong sentence or just a temporary crutch?
With drugs now rivaling surgical results, is the era of bariatric surgery for weight loss coming to an end?
Is rapid, drug-induced weight loss worth the risk of severe side effects and losing essential muscle and bone mass?
Retatrutide’s 30% Weight Loss Breakthrough: Clinical Promise, Patient Experience, and the Future of Obesity Care
Overview
This report highlights the remarkable results of retatrutide, an investigational obesity drug, through the experience of Dr. Arun Kumar, a 42-year-old physician from Kerala. Participating in a Phase 3 clinical trial, Dr. Kumar received the highest dose of 12 mg weekly injections and lost 31 kg—28.3% of his initial body weight—in just 48 weeks. His BMI dropped from 34.5 to 24.7, and his blood pressure, cholesterol, and blood sugar levels normalized. These outcomes not only showcase retatrutide’s powerful effect on weight loss but also its potential to improve overall health, as seen in global trials.